INCB-018424 (Ruxolitinib)
-
Technical Data
Description
INCB-018424 (Ruxolitinib) is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. INCB-018424 specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation.